Stocktoria
BridgeBio Pharma, Inc. BBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-06-27
BridgeBio Pharma, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M | $69.7M |
| R&D expense | $452.0M | $506.5M | $455.7M | $399.5M | $451.0M |
| SG&A expense | $531.2M | $288.9M | $150.6M | $143.2M | $192.2M |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M | -$576.6M |
| Interest expense | — | — | $81.3M | $80.4M | $46.8M |
| Income tax | $435,000 | $1.2M | $0 | $0 | — |
| Operating cash flow | -$445.9M | -$520.7M | -$527.7M | -$419.5M | -$497.9M |
| Free cash flow | -$447.0M | -$521.7M | -$529.0M | -$424.3M | -$511.2M |
| Cash & equivalents | $570.1M | $681.1M | $375.9M | $376.7M | $393.8M |
| Inventory | $26.8M | $0 | — | — | — |
| Total assets | $936.0M | $919.3M | $546.4M | $623.0M | $1.0B |
| Total liabilities | $3.0B | $2.4B | $1.9B | $1.9B | $1.9B |
| Shareholders' equity | -$2.1B | -$1.5B | -$1.4B | -$1.3B | -$870.4M |
| EPS (diluted) | $-3.78 | $-2.88 | $-3.95 | $-3.26 | $-3.90 |
Source: SEC EDGAR filings · CIK 0001743881 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.